Detecting ovarian cancer early using blood tests and advanced technology
Extracellular Vesicle Proteomic Fingerprinting of Ovarian Cancer for Early Detection with a Nanoengineered Microsystem
This study is working on a simple blood test that can spot ovarian cancer early by looking for tiny particles released by tumors, helping to catch the disease before symptoms show up and improve treatment outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kansas Medical Center NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project ID | NIH-11112335 on NIH RePORTER |
What this research studies
This research aims to develop non-invasive blood tests that can detect ovarian cancer at an early stage, which is crucial for improving patient outcomes. The approach focuses on analyzing small extracellular vesicles (sEVs) in the blood, which are released by tumors and contain important biomolecules. By utilizing advanced nanoengineered microsystems, the researchers hope to identify specific biomarkers that indicate the presence of ovarian cancer before symptoms arise. This innovative method seeks to overcome the limitations of current diagnostic techniques, which often lack sensitivity and specificity.
Who could benefit from this research
Good fit: Ideal candidates for this research include women at high risk for ovarian cancer, particularly those with BRCA1/2 mutations or a family history of the disease.
Not a fit: Patients who have already been diagnosed with advanced ovarian cancer may not benefit from this early detection research.
Why it matters
Potential benefit: If successful, this research could lead to earlier detection of ovarian cancer, significantly improving survival rates and treatment options for patients.
How similar studies have performed: Previous research has shown promise in using extracellular vesicles for cancer detection, indicating that this approach may lead to significant advancements in early diagnosis.
Where this research is happening
Kansas City, United States
- University of Kansas Medical Center — Kansas City, United States (Active)
Researchers
- Principal investigator: Godwin, Andrew K. — University of Kansas Medical Center
- Study coordinator: Godwin, Andrew K.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.